Translate

Friday, May 29, 2020

thumbnail

WPRT Westport Innovations Inc gains 28% May 29, 2020

Westport Fuel Systems Inc., a transportation technology company, provides low-emission engine and fuel system technologies utilizing gaseous fuels in North America, Europe, Asia, and South America. The company operates in four segments: Automotive, Industrial, Corporate and Technology Investments, and Cummins Westport Joint Venture. It designs, manufactures, and sells compressed natural gas (CNG), liquefied petroleum gas (LPG), and liquefied natural gas (LNG) components and systems to original equipment manufacturers and aftermarket customers. The company also designs, manufactures, tests, certifies, and sells components, such as pressure regulators, injectors, electronic control units, valves, filters, and bi-fuel, mono-fuel, and dual-fuel LPG and CNG conversion kits under the BRC Gas Equipment, Emer, OMVL, Valtek, Prins, Zavoli, GFI, and TA Gas Technology brands; fuel system components include vaporizers, and CNG and LPG tank valves; CUBOGAS branded CNG compressors and refueling systems; LPG injection systems; diesel and CNG engines; natural gas fuel systems; and Westport WiNG power system vehicles. In addition, it designs and manufactures alternative fuel components and systems for off-road mobile and stationary equipment, and heavy-duty on-road vehicles, as well as develops complete emissions certified and non-certified engines for forklifts and other industrial equipment under the IMPCO, Westport, and GFI brands. Further, the company offers natural gas engines for transit, school, and shuttle buses; conventional trucks and tractors; refuse collection trucks; and specialty vehicles, such as short-haul port drayage trucks and street sweepers. The company was formerly known as Westport Innovations Inc. and changed its name to Westport Fuel Systems Inc. in June 2016. The company was founded in 1995 and is headquartered in Vancouver, Canada.http://www.priceseries.com/trade/WPRT-Westport-Innovations-Inc-stock-gains-28-percent-a-Trade-Record-by-priceSeries-2020050820200529.html
thumbnail

TRIL Trillium Therapeutics Inc. gains 36% May 22, 2020

Trillium Therapeutics Inc., a biopharmaceutical development company, advances cancer stem cell discoveries into novel and cancer therapies in Canada. Its products comprise Tigecycline, an antibiotic, which is in phase I for study in patients with relapsed or refractory acute myeloid leukemia (AML); SIRPaFc, an antibody-like fusion protein, which is in pre-clinical stage that blocks the activity of CD47, a molecule that is upregulated on cancer stem cells in AML and other tumors; CD200, a human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule; and TTI-1612, a recombinant soluble for the treatment of interstitial cystitis (IC), a chronic bladder disease characterized by low urinary HB-EGF levels and a dysfunctional, which recently completed a 28-patient Phase I trial in IC patients. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Toronto, Canada.http://www.priceseries.com/trade/TRIL-Trillium-Therapeutics-Inc-stock-gains-36-percent-a-Trade-Record-by-priceSeries-2020050120200522.html
thumbnail

SKYS Sky Solar Holdings, Ltd. gains 101% May 29, 2020

Sky Solar Holdings, Ltd., an independent power producer, develops, owns, and operates solar parks worldwide. It develops projects; and generates and sells electricity in the downstream solar market. The company also sells solar energy systems, including pipeline and related engineering, construction, and procurement services, as well as is involved in building and transferring solar parks. In addition, it provides operating and maintenance services for solar parks; and sells solar modules. As of December 31, 2015, the company developed 273 solar parks with an aggregate capacity of 252.8 megawatts in Greece, Japan, Bulgaria, the Czech Republic, Spain, Canada, the United States, Germany and Uruguay; and owned and operated 128.6 MW of solar parks. It also had 28.2 megawatts of solar parks under construction, 238.2 megawatts of shovel-ready projects, and 1.0 gigawatt of solar parks in pipeline. Sky Solar Holdings, Ltd. was founded in 2009 and is headquartered in Central, Hong Kong. Sky Solar Holdings, Ltd. is a subsidiary of Sky Power Group Ltd.http://www.priceseries.com/trade/SKYS-Sky-Solar-Holdings-Ltd-stock-gains-101-percent-a-Trade-Record-by-priceSeries-2020042820200529.html
thumbnail

QDEL Quidel Corp. gains 58% May 22, 2020

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, POC women's and general health, and gastrointestinal diseases. The company offers Sofia influenza A+B and QuickVue influenza tests to detect viral antigens of influenza type A and B; Sofia strep A fluorescent immunoassay and QuickVue Strep A tests to detect group A Streptococcal antigen from throat swabs; and Sofia Respiratory Syncytial Virus (RSV), QuickVue RSV, and Quidel Molecular RSV + human metapneumovirus tests for respiratory syncytial virus. It also provides various products to detect various herpes simplex virus (HSV) and herpes family viruses; H&V-Mix to isolate HSV, VZV, and Cytomegalovirus; R-Mix to detect Influenza A and B, RSV, Adenovirus, and Parainfluenza types 1, 2, and 3; Sofia S. Pneomoniae fluorescent immunoassay (FIA) to detect pneumococcal pneumonia and meningitis; Sofia Legionella FIA to detect Legionella pneumophila seorgroup 1 antigen; AmpliVue Bordetella assay to detect Bordetella pertussis; and Lyra Adenovirus assay to detect human adenovirus viral DNA. In addition, the company offers Sofia hCG fluorescent immunoassay and QuickVue pregnancy tests to detect hCG in serum or urine; Thyretain for the diagnosis of graves disease; QuickVue Chlamydia test to detect Chlamydia trachomatis; Solana Trichomonas assay for the diagnosis of trichomoniasis; and clinical and research products for the assessment of osteoporosis and evaluation of bone resorption/formation. Further, it provides Lyra Direct C. difficile assay to detect Clostridium difficile Toxin A or Toxin B genes; Super E-Mix and D3 IFA Enterovirus indirect fluorescent antibody products; QuickVue fecal immunochemical test to detect the presence of blood in stool specimens; and serological tests to measure antibodies circulating in the blood. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.http://www.priceseries.com/trade/QDEL-Quidel-Corp-stock-gains-58-percent-a-Trade-Record-by-priceSeries-2020042020200522.html
thumbnail

ONCS OncoSec Medical Incorporated gains 15% May 29, 2020

OncoSec Medical Incorporated, a biotechnology company, designs, develops, and commercializes gene therapies, therapeutics, and proprietary medical approaches to stimulate and guide an anti-tumor immune response for the treatment of cancer in the United States. Its lead product candidate is the ImmunoPulse IL-12, which is in Phase II clinical trial for various indications, including metastatic melanoma and triple negative breast cancer. ImmunoPulse is an electroporation delivery device used in combination with the company's therapeutic product candidates, including DNA plasmids that encode for immunologically active agents, and to deliver the therapeutic directly into the tumor and promote an inflammatory response against the cancer. The company also has completed two Phase II studies for products, such as OMS-I100 in metastatic melanoma and OMS-I110 in merkel cell carcinoma. It has a clinical collaboration with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.http://www.priceseries.com/trade/ONCS-OncoSec-Medical-Incorporated-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2020051820200529.html
thumbnail

NWHM New Home Company Inc. (The) gains 23% May 29, 2020

The New Home Company Inc., a homebuilder, focuses on the design, construction, and sale of homes in metropolitan areas of California and Arizona. The company operates through two segments, Homebuilding and Fee Building. It builds and sells homes in California, including coastal Southern California, the San Francisco Bay area, the metro Sacramento, and the Phoenix area. The company also offers general contracting services to build homes for independent third-party property owners. The New Home Company Inc. was founded in 2009 and is headquartered in Aliso Viejo, California.http://www.priceseries.com/trade/NWHM-New-Home-Company-Inc-The-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2020051520200529.html
thumbnail

NSS NuStar Logistics, L.P. gains 44% May 29, 2020

NuStar Logistics, L.P. engages in the terminalling, storage, and transportation of petroleum products; the transportation of anhydrous ammonia; and the refining and marketing of petroleum. The company operates in three segments: Storage, Transportation, and Asphalt and Fuels Marketing. The Storage segment operates terminal and storage facilities that provide storage and handling services for petroleum products, specialty chemicals, crude oil and other feedstocks, and other liquids; and storage tanks that are used to store and deliver crude oil. This segment also provides various services, such as blending, filtering, pilotage, tug assistance, line handling, launch, emergency response, and other ship services. The Transportation segment transports refined petroleum products, crude oil, and anhydrous ammonia. The Asphalt and Fuels Marketing segment refines crude oil to produce asphalt and certain other refined products; and purchases crude oil and other refined petroleum products for resale. NuStar Logistics serves producers of crude oil, integrated oil companies, chemical companies, oil traders and refiners, farm cooperatives, railroads, and road and bridge construction companies. The company is headquartered in San Antonio, Texas. NuStar Logistics, L.P. is a subsidiary of Nustar Energy L.P.http://www.priceseries.com/trade/NSS-NuStar-Logistics-LP-stock-gains-44-percent-a-Trade-Record-by-priceSeries-2020040820200529.html
thumbnail

INSM Insmed, Inc. gains 25% May 29, 2020

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.http://www.priceseries.com/trade/INSM-Insmed-Inc-stock-gains-25-percent-a-Trade-Record-by-priceSeries-2020041720200529.html
thumbnail

DVAX Dynavax Technologies Corp. gains 22% May 22, 2020

Dynavax Technologies Corporation, a clinical-stage immunotherapy company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. The company's lead product candidates include HEPLISAV-B, an investigational adult hepatitis B vaccine, which is in Phase III clinical trials; and SD-101, an investigational cancer immunotherapeutic that is in Phase I/II studies. Its product candidates also comprise AZD1419, which is in Phase II clinical trial for the treatment of asthma; DV230F that is in preclinical stage for the treatment of liver tumors; and DV1001, a TLR 7&8 agonist, which is in preclinical stage for the treatment of for multiple malignancies, as well as DV281 for the treatment of non-small cell lung cancer. It has collaboration and license agreements with AstraZeneca AB to develop AZD1419 for the treatment of asthma; and Merck & Co. to develop SD-101 for varios immuno-oncology therapies. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, California.http://www.priceseries.com/trade/DVAX-Dynavax-Technologies-Corp-stock-gains-22-percent-a-Trade-Record-by-priceSeries-2020051420200522.html

TradeVisor Product Review

Review I II III IV

Blog Archive